Quince Therapeutics Inc
QNCX
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.4M
Close$
$-0.20
100.6% downside
Current Fair Value
100.6% downsideOvervalued by 100.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.40 Million |
|---|---|
| Enterprise Value | $-106,584,730.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-336 |
| Beta | 1.4 |
| Outstanding Shares | 6,132,845 |
Return
| Return on Equity | 261.79% |
|---|---|
| Return on Assets | -74.58% |
| Return on Invested Capital | -104.10% |
Valuation & Multiples
| P/E Ratio | -0.49 |
|---|---|
| PEG | -0.13 |
| Price to Sales | - |
| Price to Book Ratio | 1.89 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.89 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-28.02
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-4.03
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6897▲ 59.08% |
|---|---|
| Total Calls | 170,800▼ 82.33% |
| Total Puts | 117,800▲ 23.22% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.27%▼ 0.91% |
|---|---|
| Total Invested | $6.00M▲ 173.45% |
| Investors Holding | 30▼ 21.00% |
ESG Score
No data
About Quince Therapeutics Inc
38 employeesCortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence genera...